New mesothelioma drug turns cancer’s own defenses against it

Scientists are testing a counterintuitive way to fight mesothelioma, an aggressive asbestos-linked cancer with few effective treatments. A new experimental mesothelioma drug kills cancer cells by disabling PRX3, an antioxidant defense that tumors use to survive intense oxidative stress. In an early clinical trial, it controlled disease progression in 67% of patients and produced encouraging survival results, raising hopes that the strategy could eventually be used against other cancers.